N. Miller

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

M. Gerritsen, D. J. Matthews, V. Vysotskaia, 2008, Clinical Cancer Research.

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

K. Yamaguchi, J. Nuss, J. Woolfrey, 2013, Journal of medicinal chemistry.

Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.

Wei Xu, D. J. Matthews, J. Nuss, 2012, Bioorganic & Medicinal Chemistry Letters.

Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

L. Karnitz, D. J. Matthews, Y. D. Kim, 2007, Cell cycle.

Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.

Wei Xu, D. J. Matthews, J. Nuss, 2012, Bioorganic & medicinal chemistry letters.

The Tox21 robotic platform for the assessment of environmental chemicals--from vision to reality.

Ruili Huang, P. Shinn, C. Austin, 2013, Drug discovery today.

Identification of Thyroid Hormone Receptor Active Compounds Using a Quantitative High-Throughput Screening Platform

Ruili Huang, Menghang Xia, Keith Houck, 2014, Current chemical genomics and translational medicine.